Withthe MURANO study of the first-in-class BCL-2 inhibitor Venclexta in the broad relapsed chronic lymphocytic leukemia population done and dusted and front-line studies chugging along, partners Roche and AbbVie Inc. are busy writing the drug's next chapters, with a special focus on expansion into acute myeloid leukemia and multiple myeloma.
Venclexta (venetoclax) is an oral drug that blocks the BCL-2 protein in order to restore the signaling system that tells...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

